5 Atopic Dermatitis Clinical Trials in Fort Smith, AR (2026)

Q: How do I join a clinical trial in Fort Smith?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Fort Smith research site will contact you.

Recruiting Atopic Dermatitis Studies in Fort Smith

NCT06073431Recruiting

LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia

This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be r...

Fort Smith, AR800 participantsUniversity of Rochester

View Study Details

NCT06947993Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD)....

Fort Smith, ARPHASE2224 participantsNovartis Pharmaceuticals

View Study Details

NCT02734537Recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. ...

Fort Smith, ARPHASE2189 participantsECOG-ACRIN Cancer Research Group

View Study Details

NCT07244263Recruiting

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may bec...

Fort Smith, ARPHASE290 participantsTakeda

View Study Details

NCT03739814Recruiting

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly ...

Fort Smith, ARPHASE284 participantsNational Cancer Institute (NCI)

View Study Details

About Atopic Dermatitis Clinical Trials in Fort Smith

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 5 atopic dermatitis clinical trials recruiting participants in Fort Smith, AR. These studies are seeking a combined 1,387 participants. Research is being sponsored by University of Rochester, Novartis Pharmaceuticals, ECOG-ACRIN Cancer Research Group and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Fort Smith — FAQ

Are there atopic dermatitis clinical trials in Fort Smith?

Yes, there are 5 atopic dermatitis clinical trials currently recruiting in Fort Smith, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fort Smith?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fort Smith research site will contact you about next steps.

Are clinical trials in Fort Smith free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fort Smith studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 5 active trials in Fort Smith are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated July 22, 2026 from ClinicalTrials.gov